There is no single best medicine for COPD. The right treatment depends on how severe your symptoms are, how often you experience flare-ups, and specific markers in your blood. Most people start with one or two inhaled medications and add more over time if needed. Here’s how the main treatment options compare and who benefits most from each.
Inhaled Bronchodilators: The Starting Point
Nearly everyone with COPD begins treatment with a long-acting inhaled bronchodilator. These medications relax the muscles around your airways, making it easier to breathe. There are two types: one works on a different set of receptors than the other, and they’re often combined for a stronger effect. You’ll hear them referred to by their class abbreviations, LAMA and LABA, but what matters is what they do. LAMAs block signals that tighten your airways, while LABAs stimulate receptors that open them up.
For most people with stable COPD and no recent flare-ups, starting with a LAMA/LABA combination inhaler is the standard first step. These dual bronchodilator inhalers improve breathing more than either type alone and are available as a single device you use once or twice a day. If your COPD is mild, a single bronchodilator may be enough on its own.
Short-acting “rescue” inhalers also play a role. These work within minutes and are meant for sudden breathlessness, not daily maintenance. If you’re reaching for your rescue inhaler more than a few times a week, your maintenance regimen likely needs adjustment.
When Inhaled Steroids Make a Difference
Adding an inhaled corticosteroid (ICS) to your bronchodilators is not automatically better. In fact, for the wrong patient, it can increase risks like pneumonia without providing much benefit. The key factor is a blood marker called eosinophils, a type of white blood cell involved in inflammation.
Current guidelines recommend considering an ICS when your blood eosinophil count is 150 cells per microliter or higher. Below that threshold, the likelihood of benefit drops significantly, and the potential for harm rises. Your doctor can check this level with a simple blood draw.
The other major factor is flare-up history. Real-world data shows that adding an ICS to a bronchodilator combination works best in people who have had two or more exacerbations in the past year, particularly those whose lung function is still relatively preserved (at or above 50% of predicted capacity). For people with no prior flare-ups and more severely reduced lung function, ICS-containing combinations actually performed worse than dual bronchodilators alone.
Triple Therapy for Severe COPD
Triple therapy combines all three medication types into a single inhaler: a LAMA, a LABA, and an ICS. This is the most potent inhaler-based option available, and it’s reserved for people whose symptoms or flare-ups aren’t controlled on two medications.
What makes triple therapy stand out is its effect on survival. Two large clinical trials found that triple therapy reduced the risk of death compared to dual bronchodilator treatment alone. In one trial (IMPACT), the risk of dying from any cause dropped by 28%. In the other (ETHOS), it dropped by 49%. These are meaningful numbers for a disease where exacerbations can be life-threatening, and they represent some of the strongest mortality evidence for any COPD treatment.
Triple therapy isn’t right for everyone. It carries a higher risk of pneumonia than non-steroid options, and the survival benefit appears strongest in people with elevated eosinophils and frequent flare-ups. If you’re doing well on two medications, stepping up to three just for the sake of it doesn’t help.
Oral Medications That Reduce Flare-Ups
When inhalers alone aren’t enough to prevent exacerbations, an oral anti-inflammatory pill can be added. Roflumilast is the most established option. It works by reducing a specific type of inflammation in the lungs, and it’s designed for people with a chronic bronchitis pattern of COPD (meaning persistent cough and mucus production) who continue to have flare-ups despite maximal inhaler therapy.
In pooled clinical trial data, roflumilast reduced the rate of moderate or severe exacerbations by roughly 17% to 19% compared to placebo. That benefit held whether or not patients had previously been on inhaled steroids. The trade-off is side effects: nausea, diarrhea, and weight loss are common, and some people can’t tolerate the medication long-term.
Preventive Antibiotics for Frequent Flare-Ups
For people who experience two or more exacerbations per year despite being on maximal inhaler therapy, a low-dose antibiotic taken long-term can help prevent flare-ups. Azithromycin is the antibiotic used for this purpose, typically at 250 mg daily or 250 to 500 mg three times a week.
This approach is a last-line strategy. Guidelines from the Agency for Healthcare Research and Quality specify that prophylactic antibiotics should only be considered after all non-antibiotic options, including bronchodilators and anti-inflammatory medications, have been maximized. Long-term antibiotic use carries risks including hearing changes and antibiotic resistance, so it’s reserved for people whose flare-ups remain frequent and severe despite everything else.
A New Option for Eosinophilic COPD
In 2025, the FDA approved dupilumab as the first biologic medication for COPD. Biologics are injectable drugs that target specific parts of the immune system, and dupilumab blocks two inflammatory signals that drive a particular type of airway inflammation. It’s approved specifically for adults with inadequately controlled COPD and an eosinophilic phenotype, meaning their disease is driven by elevated eosinophil activity.
The results from two large trials were notable. In the BOREAS trial, people on dupilumab had 0.78 moderate or severe exacerbations per year compared to 1.10 on placebo, a 29% reduction. In the NOTUS trial, the reduction was even larger at 34%. Lung function also improved: patients on dupilumab gained about 70 to 80 mL more breathing capacity than those on placebo over one year.
Dupilumab is given as a subcutaneous injection every two weeks and is added on top of existing inhaler therapy, not used instead of it. Side effects in trials were relatively mild. Injection site reactions occurred in about 3% of patients compared to less than 1% on placebo, and viral infections were slightly more common. This medication fills a gap for people with eosinophil-driven COPD who remain symptomatic despite triple therapy, but it’s not appropriate for all COPD patients.
How Treatment Builds Over Time
COPD treatment follows a step-up approach. You start with the least amount of medication needed to control your symptoms and add more if your disease progresses or flare-ups become more frequent. A typical progression looks like this:
- Step 1: A single long-acting bronchodilator (LAMA or LABA)
- Step 2: Dual bronchodilator therapy (LAMA plus LABA in one inhaler)
- Step 3: Triple therapy (LAMA plus LABA plus ICS), guided by eosinophil levels and exacerbation history
- Step 4: Add-on oral medications like roflumilast, preventive antibiotics, or dupilumab for eosinophilic disease
Your blood eosinophil count is one of the most useful pieces of information for guiding these decisions. If your count is below 150 cells per microliter, steroid-containing options are less likely to help you, and your treatment path will lean more heavily on bronchodilators and non-steroid add-ons. If your count is higher, ICS-containing inhalers and potentially dupilumab become much more relevant. Asking your doctor about your eosinophil level is one of the most practical things you can do to understand which medications are likely to work best for you.